BUZZ-Chime shares surge after raising annual revenue growth forecast
路透社2026/11/04 23:16November 4 - ** After the fintech company Chime raised its 2026 revenue growth forecast, its shares CHYM.O rose 8.7% in after-hours trading to $32.5
** According to analysts surveyed by LSEG, Chime now expects a 28% revenue growth rate for 2026, compared to the prior market consensus of 26.6%.
** CHYM expects fourth-quarter revenue to be between $757 million and $767 million, above analysts’ estimate of $745.6 million
** “We are seeing... member spending growth continue to outperform inflation, maintaining very strong momentum in both what we call ‘discretionary spending’ and ‘non-discretionary spending,’” President and Interim Chief Financial Officer Mark Troughton told Reuters
** Out of 26 brokerages, 24 rate the stock as “buy” or higher, and 2 rate it as “hold”; the median target price is $40
** As of the close of the previous trading day, Chime has risen 18.7% so far this year
(To facilitate non-native English speakers, Reuters provides automated translations of its reports into several other languages. Due to possible errors in automated translation or the lack of contextual nuances, Reuters does not guarantee the accuracy of automated translation text and provides it solely for reader convenience. Reuters accepts no responsibility for any damage or losses caused by the use of automated translation functions.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).

Tom Lee Says Democratic Sweep Could Fuel 15% to 20% Tech Rally
